/PRNewswire/ Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced preliminary clinical data for.
Affimed (AFMD) Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Affimed (AFMD) to Present Preclinical Data Demonstrating Cytotoxic Activity of AFM28 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells via antibody-dependent cellular cytotoxicity.AFM28.